Drug Trial Radar · NCT01336153
Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke
Last checked: Nov 19, 2026Latest source record: May 2, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Aug 2009
Primary completion
Jan 2010
Study completion Dec 2010
Sponsor
- Lead sponsor
- Shahid Beheshti UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shahid Beheshti University of Medical Sciences
- First posted
- Apr 15, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 72 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the safety and efficacy of MLC601 (NeuroAideTM) as a Traditional Chinese Medicine on motor recovery after ischemic stroke.
Conditions
- Stroke
Interventions
MLC601Drug
group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
PlaceboDrug
group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigate the Safety and Efficacy of MLC601Time frame: 18 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.